Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Arteris, Inc.'s SEC filings can feel like navigating a dense wiring diagram—hundreds of pages on deferred royalties, automotive safety certifications, and stock-based compensation. If you need the revenue backlog buried in a 10-K or want to spot Form 4 trades before the next design-win press release, the traditional EDGAR search simply takes too long.
Stock Titan solves this problem. Our AI-powered summaries translate complex semiconductor accounting into plain language, flagging key metrics such as licensing revenue mix, R&D capitalization trends, and customer concentration. Real-time alerts pull every Arteris quarterly earnings report 10-Q filing, 8-K material events explained in minutes, and Arteris insider trading Form 4 transactions as they post—so you never miss a disclosure.
Here’s what you can uncover instantly:
- Arteris annual report 10-K simplified—royalty schedules, risk factors, and segment performance distilled within seconds.
- Arteris Form 4 insider transactions real-time—track executive stock sales or option exercises alongside AI context on upcoming product milestones.
- Proxy statement executive compensation—see how design-win milestones affect equity awards without combing through tables.
- Arteris earnings report filing analysis—compare quarter-over-quarter gross margin shifts and R&D intensity.
Whether you’re monitoring executive stock transactions, assessing patent litigation exposure, or just trying to understand Arteris SEC filings explained simply, our platform surfaces the data professionals rely on—no jargon, no delays.
Arteris, Inc. is using a shelf registration to potentially offer up to
Within this shelf, the company may issue and sell shares of common stock with an aggregate offering price of up to
Arteris is a leading provider of semiconductor System IP, including interconnect Networks-on-Chips used in complex System-on-Chip designs, with growth driven by rising chip complexity and AI applications. Its common stock is listed on the Nasdaq Global Market under the symbol AIP, and the last reported sale price was
Arteris, Inc. director K. Charles Janac reported an indirect sale of company stock executed under a pre-arranged trading plan. On December 4, 2025, an entity he manages, Bayview Legacy, LLC, sold 40,000 shares of Arteris common stock at a weighted average price of $16.4618 per share under a Rule 10b5-1 plan adopted on March 5, 2025. Following this transaction, Janac beneficially owned 9,599,071 shares of Arteris common stock indirectly through Bayview Legacy, LLC.
Arteris, Inc. (AIP) — Form 4 insider transaction: On 11/10/2025, a reporting person sold 50,000 shares of common stock at a weighted average price of $14.7366, coded as an open-market sale (S). The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2025.
Following the transaction, the reporting person beneficially owned 9,639,071 shares, held indirectly through Bayview Legacy, LLC. The filer is identified as a Director. The price range for the sales was $14.34 to $14.95, with details available upon request.
Arteris, Inc. (AIP) disclosed an insider transaction: Chief Operating Officer Moll Laurent R. sold 32,775 shares of common stock on 11/05/2025 at a weighted average price of $15.4233. The shares were sold in multiple trades within a price range of $14.90–$15.90.
The transactions were executed under a Rule 10b5-1 trading plan adopted on March 12, 2025. After the sale, the reporting person beneficially owns 311,110 shares directly.
Arteris, Inc. (AIP) reported an insider transaction by its VP and General Counsel. On 11/03/2025, the officer exercised 5,000 options at $0.56 per share (code M) and sold 5,000 shares at a weighted average price of $13.162 (code S), with sale prices ranging from $12.98 to $13.59. The trades were made under a Rule 10b5‑1 trading plan adopted on June 5, 2025. Following the transactions, the officer reported 65,960 shares of common stock held directly and 80,000 derivative securities remaining. The option underlying the exercised shares expires on 10/23/2029, with vesting that began in 2020.
Arteris, Inc. (AIP) reported Q3 2025 results with total revenue of $17.4 million, up from $14.7 million a year ago as licensing, support and maintenance reached $15.9 million and variable royalties were $1.5 million. Gross profit was $15.6 million on a 90% gross margin profile. Operating expenses rose to $24.4 million, leading to a net loss of $9.0 million versus $7.7 million last year, or $0.21 per share.
The company ended September 30, 2025 with $17.4 million in cash and cash equivalents and $43.2 million in total investments. Deferred revenue was $85.9 million, and remaining performance obligations were $104.7 million. Annual Contract Value was $69.4 million, with ACV plus royalties at $74.9 million as of September 30, 2025. Net cash provided by operating activities for the nine months was $3.6 million.
Arteris reported 23 Confirmed Design Starts in the quarter. As of October 28, 2025, there were 43,683,773 common shares outstanding. In litigation, on September 4, 2024, a Texas federal court dismissed all claims against the company without prejudice in the NST matter.
Arteris, Inc. furnished a Form 8‑K stating it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The company noted that the information in Items 2.02 and 9.01, including Exhibit 99.1, is being furnished and not deemed “filed” under the Exchange Act. Arteris’ common stock trades on Nasdaq under the symbol AIP.
Arteris, Inc. reporting person Janac K. Charles disclosed insider sales executed under a 10b5-1 trading plan adopted on
Arteris, Inc. (AIP) reporting person Bayview Legacy, LLC (managed by K. Charles Janac) sold 50,000 shares of common stock on
Insider sale under 10b5-1 plan. The filing shows that Nicholas B. Hawkins, Vice President and Chief Financial Officer of Arteris, Inc. (AIP), sold 6,421 shares of common stock on
FAQ
What is the current stock price of Arteris (AIP)?
What is the market cap of Arteris (AIP)?
